These findings support the potential clinical utility of CHIP testing for cardiovascular risk stratification for patients with solid tumors undergoing cancer treatment and suggest that incorporating CHIP status may improve cardio-oncology treatment of cancer survivors. The gene discussed is STUB1; the disease is cancer.